Board of Directors

 

Amir Belson, M.D.

Prior to conceiving of and starting ZipLine® Medical, Amir Belson, M.D., was the founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures that was later acquired by Intuitive Surgical in 2009.  Belson is also the founder of Vascular Pathways, a company that developed an FDA cleared vascular intervention technology that has been chosen as one of the 10 best inventions of 2009 by Popular Science magazine, Thermocure, a minimally invasive therapeutic hypothermia technology company, Radguard Medical, a radiation protection medical device company and VasoStitch, which develops large vessel access and closure technology.

Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel.  He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford.  He also served several years as a flight surgeon in Israel’s air force rescue unit before moving to the US for a three year Pediatric Nephrology fellowship at Stanford University Medical Center.  Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.

Patrick Berbon, Ph.D.

Patrick has an extensive background in metallurgy, aerospace, power and cleantech industries. Before co-founding China Materialia, Patrick was a Senior Consultant at Performance Improvement, a risk analysis and management company specialized in power industries. Patrick is an experienced entrepreneur in the advanced materials space. His prior start-up focuses on advanced nanograin aluminum alloys and its applications, the company was successfully listed on the Toronto Venture Exchange. Before his entrepreneurial ventures, Patrick was a Senior Scientist in Materials Science Division at Rockwell Scientific Inc. Patrick specializes in advanced materials and clean technologies, including renewable electricity generation, biofuels for transportation, green building, clean water, clean air, carbon dioxide emissions reduction, recyclable materials, sustainable foresting and agriculture, and energy efficiency. Patrick obtained his Ph.D. from the University of Southern California, Los Angeles, his M.S. from Tsinghua University (China) and M.S./B.S. from Ecole Centrale de Lyon (France), all in Materials Sciences. Patrick is a member of the Board of Directors of Camray, Octadem and Wesmart.

 

Bali Muralidhar, M.D. Ph.D.

Bali joined MVM in 2012. Before joining he was a key member of Bain Capital’s healthcare deal team. Prior to that he was a management consultant in Bain & Company’s healthcare team. Bali obtained a degree in Clinical Medicine from Oxford University and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, Cambridge University, and has published over a dozen peer reviewed papers.

Bali is a member of the boards of Onbone Oy, Wilson Therapeutics AB and Zipline Medical, Inc.

Stephen Reeders, M.D.

Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.

Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas’s Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.

Steve is a member of the boards of Ambio, Inc., Cheetah Medical, Inc., Pulmagen Therapeutics Ltd and Zipline Medical, Inc. He was previously a director of Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., UpToDate, Inc., Xention Ltd and Vascular Pathways, Inc.

 

John R. Tighe

John R. Tighe serves as Chief Executive Officer and president of ZipLine Medical, Inc.  He also serves as a member of ZipLine’s board of directors.  Prior to joining ZipLine, he was the CEO and president of PEAK Surgical, Inc. from 2006 to 2011.  He was the first employee and also served as a Director of PEAK Surgical until their acquisition by Medtronic in 2011.  Mr. Tighe has over 22 years of experience in the medical device industry and has worldwide commercialization experience in several medical  specialties, including orthopaedics, ENT, and general surgery.  Prior to PEAK Surgical he was senior vice president and general manager of all business units for ArthroCare Corp, where he worked for 11 years.  Before that, he served as national sales manager for Acufex Microsurgical, where he worked in various sales and management roles over a seven year period.  Mr. Tighe holds a B.S. degree in Civil Engineering from the University of Maryland.

 

Dean Tozer

Dean Tozer has more than 25 years of experience in the global healthcare industry with an established track record of successfully launching and marketing innovative technologies. Mr. Tozer currently works as a consultant/advisor in the field of commercial and corporate strategy. His clients include HighCape portfolio companies as well as other commercial-stage start-up organizations.

Prior to his current role, he was President & CEO of Nuo Therapeutics, a biomedical company that markets innovative wound care products. He joined Nuo following his tenure as Vice President of Corporate Development for Shire Regenerative Medicine, where he led business development efforts for that division, including the 2012 acquisition of Pervasis Therapeutics. Tozer arrived at Shire through the 2011 acquisition of Advanced BioHealing, where he was Senior Vice President since the company’s inception in 2006. He is widely regarded as a key architect of the commercial strategy behind the re-launch and subsequent success of Dermagraft in the U.S. market.

Prior to working with early stage companies, he spent 10 years in the global pharmaceutical industry and lived in Toronto, Chicago and Tokyo while commercializing global blockbuster products such as Bextra & Celebrex.

From 2009 to 2013, Mr. Tozer also served as a founding executive and officer of The Alliance for Regenerative Medicine. He received a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Nova Scotia and a Certified Management Accountant designation in Ontario, Canada.